Project Grant HT94252510283

The federal Project Grant award, provided by the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394), is focused on developing noninvasive imaging and blood-based biomarkers to improve prediction of immunotherapy response and clinical outcomes for patients with advanced non-small cell lung cancer (NSCLC). The $1,820,020 award, which runs from May 2024 to April 2029, will support research to: (1) create knowledge-guided radiomics and deep...

This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) supports the development of a novel circulating tumor DNA (ctDNA) assay technology by Binary Genomics, Inc. to monitor the efficacy of immunotherapy treatments for non-small cell lung cancer. The $398,040 award over 18 months will enable the company to evaluate the analytical and baseline clinical performance of their ctDNA assay, which aims to address limitations of existing...

This federal Project Grant award for $2,278,505 from the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394) aims to develop a novel prototype system to enable real-time 3D tumor tracking during stereotactic body radiotherapy (SBRT) for lung cancer. The project, led by researchers at The Johns Hopkins University, seeks to overcome a critical challenge in 4D radiotherapy by using a system that measures scattered x-ray photons to image the...

This Project Grant award from the National Cancer Institute (NCI), under the federal Cancer Detection and Diagnosis Research program (CFDA 93.394), aims to develop an innovative circulating tumor DNA (ctDNA) assay technology for monitoring the efficacy of immunotherapy treatments in non-small cell lung cancer patients. The $990,771 award to Binary Genomics, Inc. over the 2-year project period from 09/2024 to 08/2026 will support advancing the company's epigenetic-based ctDNA detection approach...

The National Cancer Institute (NCI) awarded a $1,280,908 Project Grant (CFDA 93.394 - Cancer Detection and Diagnosis Research) to Exai Bio Inc., a small disadvantaged business located in Palo Alto, California. The grant will fund the development of a novel liquid biopsy assay and artificial intelligence (AI) model for early detection of non-small cell lung cancer (NSCLC) and prediction of NSCLC subtypes. The project aims to validate the performance of this new assay for detection of minimal...

This Project Grant award from the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), provides $1,625,000 to Onc.ai, Inc. to validate radiomics-based multi-modal predictive models for assessing response to PD-(L)1 immunotherapy in Stage IV non-small cell lung cancer patients. The key objectives are to: 1) prospectively validate the predictive models in a multi-institutional clinical study; 2) evaluate the models' performance characteristics...

This $399,499 Project Grant award from the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), supports the development of Liquid Biotech's TELOMESCAN circulating tumor cell (CTC) assay for monitoring non-small cell lung cancer (NSCLC) patients undergoing radiation and immunotherapy. The key products and services to be delivered through this funding include: 1) Developing a clinical prototype of the TELOMESCAN assay with automated analysis to...

The National Cancer Institute (NCI), under the federal Cancer Detection and Diagnosis Research program (CFDA 93.394), awarded a $1,999,108 Project Grant to Orbit Genomics, Inc. for the "Development of a Lung Cancer Subtyping Diagnostic." The goal of this project is to create a highly sensitive and specific diagnostic test to accurately subtype lung cancer, which is critical for selecting the most effective treatment and reducing mortality. This new subtyping capability will be...

This Project Grant award from the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), provides $678,228 to The General Hospital Corporation (doing business as Massachusetts General Hospital) to develop GLISCAN, a multi-analyte, multi-mutation blood-based assay for rapid, sensitive molecular subtyping of gliomas. The project aims to optimize, verify, and validate GLISCAN in adherence with industry standards, with the intention of...

This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $679,188 to The Regents of the University of California, San Francisco to develop liquid biopsy tools for detecting and profiling malignant effusions associated with metastatic breast cancer. The key objectives are to: 1) Validate an AI-assisted, morphology-based platform to isolate circulating tumor cells from malignant effusions; 2) Perform molecular characterization...